UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
This guide clarifies which investors benefit most from target date funds versus index funds, focusing on goals and involvement level.
26,623 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Synopsys posted solid quarterly results but faces Design IP headwinds. The path to a 2027 price target hinges on marg...
As the quarter winds down, Monday’s best Wall Street calls set the tone, spotlighting tech, energy and consumer names...
Public scrutiny can spill over into family finances. This article examines Gary Coleman’s ex-wife faces renewed quest...
A new tax window for workers aged 60-63 could alter retirement planning. The $246,500 question: your 401(k) highlight...
As of June 2026, households pursue financial independence by targeting $7,500 a month in dividend income to replace a...
UBS cuts Mosaic’s price target to $27, citing squeezed phosphate margins from higher sulfur and input costs, as Wall ...
UBS raises AMD’s target to $670, a sharp upgrade that highlights strong AI-driven data center demand. Traders watch f...
Apple reported a strong quarter with better-than-expected growth across iPhone and Services. Analysts say apple’s tar...
A four-name AI momentum basket — NVIDIA, AMD, Palantir and TESLA — drives 2027–2029 price targets as AI demand and EV...
Markets are sizing Coca-Cola for a two-year path as AI-driven capital shifts reshape sectors. A fresh price predictio...
Losing a beloved figure reminds us that our finances can echo values we hold dear. This article turns grief into prac...